Eurofins Central Laboratory Expands US Lab Operations to PA Campus
Eurofins Central Laboratory announced the expansion and relocation of its US Central Laboratory Operations to the company's Pharma Services campus in Lancaster, PA.
Eurofins Central Laboratory announced the expansion and relocation of its US Central Laboratory Operations to the company's 330,000 square foot Pharma Services campus in Lancaster, PA. The consolidation of the company's Central Laboratory with its Lancaster Laboratories comes amongst the recently announced acquisitions of US bioanalytical, discovery, genomic and diagnostic laboratories. The purpose built Central Laboratory is essential to the global footprint of wholly-owned laboratory facilities in the United States, Europe,Asia and China.
Read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
